Industry: Healthcare
Published Date: July-2024
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 189
Report ID: PMRREP34649
The global market is estimated to value at US$30.3 Bn by the end of 2031 from US$22.7 Bn anticipated in 2024. The market is expected to secure a CAGR of 4.2% from 2024 to 2031.
Key Highlights of the Market
• Increasing demand for biologics and gene therapy hold a measurable impact on market expansion.
• The personalized medicine and precision therapy trends will be vital towards the growth of market revenue.
• Regulatory agencies are implementing fast-track approval processes for breakthrough MI therapies, accelerating the time to market.
• Development of new antithrombotic drugs with improved safety profiles and efficacy is enhancing MI treatment options.
|
Market Attributes |
Key Insights |
|
Myocardial Infarction (MI) Therapeutics Market Size (2024E) |
US$22.67 Bn |
|
Projected Market Value (2031F) |
US$30.3 Bn |
|
Forecast Growth Rate (CAGR 2024 to 2031) |
4.2% |
|
Historical Growth Rate (CAGR 2019 to 2024) |
5.4% |
A heart attack is known medically as a myocardial infarction. A heart attack is a potentially fatal disorder that arises from an abrupt interruption of blood flow to the heart muscle, leading to tissue damage.
Typically, a blockage in one or more coronary arteries is the source of this. Plaque accumulation, which is mostly made up of fat, cholesterol, and cellular waste materials, might result in a blockage.
Sweating, nausea, heartburn, and chest pain or discomfort are signs of myocardial infarction. Age, smoking, high blood pressure, obesity, diabetes, use of illegal drugs, stress, and other risk factors all lead to atherosclerosis, an undesired build-up of fatty deposits that narrows arteries throughout the body and increases the risk of heart attacks.
Heart attacks can be treated with drugs such aspirin, antiplatelet medicines, or painkillers. Heart attacks can be treated with drugs as well as treatments like coronary angioplasty and stenting.
During this treatment, a long, thin tube called a catheter is directed through an artery in the wrist or groin to a blocked artery in the heart. If necessary, coronary artery bypass surgery can be carried out to replenish the blood flow to the heart muscle.
Market growth is primarily driven by an increasing prevalence of cardiovascular diseases, advancements in medical technology, and growing awareness of heart health. The market encompasses various treatment options, including medications, surgical procedures, and lifestyle modifications.
Major advancements influencing the market include next-generation antiplatelet and antithrombotic therapies, personalized and precision medicine, regenerative medicine, digital health and telemedicine integration, novel drug delivery systems, immunotherapy and anti-inflammatory strategies, AI and machine learning, and global collaborations.
These crucial market trends are reshaping the landscape of MI treatment, offering new opportunities for improved patient outcomes and advancing the field of cardiovascular medicine.
-therapeutics-market.webp)
The Myocardial Infarction (MI) Therapeutics Market has experienced steady growth from 2018 to 2023, driven by an increasing prevalence of cardiovascular diseases, advancements in treatment options, and rising healthcare expenditure.
Looking ahead, the market is expected to continue its upward trajectory, fuelled by innovations in personalized medicine, regenerative therapies, digital health integration, and rising healthcare expenditure.
Despite challenges related to treatment costs, regulatory hurdles, and safety concerns, the market holds significant potential for further expansion and improved patient outcomes through continued research, development, and global collaboration.
Ongoing advancements in drug delivery systems, including nanotechnology and controlled-release formulations, are expected to improve the efficacy and safety of MI therapeutics.
Further integration of digital health solutions and AI-driven technologies will enhance patient monitoring, early detection, and personalized treatment approaches.
Increasing Heart Attack Cases Worldwide
The rising incidence of heart attacks, also known as myocardial infarctions (MIs), is a significant driver of growth in the myocardial infarction therapeutics market. Several factors contribute to this increase, which, in turn, amplifies the demand for effective treatments and interventions.
The increasing cases of heart attacks globally are a significant driver for the myocardial infarction therapeutics market.
Factors such as the rising incidence of cardiovascular diseases, growing awareness and early diagnosis, advancements in treatment options, increasing healthcare expenditure, improved healthcare infrastructure, technological innovations in diagnostics and treatment, and supportive reimbursement policies are all contributing to the market's growth.
As the demand for effective MI therapeutics continues to rise, companies in this sector are well-positioned to innovate and expand their offerings, ultimately improving patient outcomes and reducing the global burden of myocardial infarction.
High Cost of Treatment
Advanced MI therapeutics, including novel drug formulations and regenerative therapies, can be costly. High treatment costs can limit access for patients, particularly in low- and middle-income countries.
The overall economic burden of MI, including hospitalization, long-term care, and medication costs, can strain healthcare systems and affect affordability for patients.
Myocardial infarction therapeutics market holds significant potential for growth and innovation, it also faces numerous restraints that could impede progress.
Addressing challenges related to high treatment costs, regulatory hurdles, safety concerns, and access to healthcare will be crucial for companies to navigate and succeed in this dynamic market.
Strategic planning, investment in R&D, and collaboration with healthcare stakeholders will be essential to overcome these restraints and deliver effective MI therapies to patients worldwide.
Advancements in Precision Medicine and Genomics
Leveraging genetic information to develop personalized treatment plans can significantly enhance therapeutic efficacy and reduce adverse effects. Companies can invest in precision medicine to create tailored therapies for MI patients based on their genetic profiles.
The future of the myocardial infarction therapeutics market holds numerous opportunities for companies willing to innovate and adapt. By focusing on precision medicine, advanced drug delivery systems, regenerative medicine, digital health integration, and global market expansion, companies can drive significant advancements in MI treatment and improve patient outcomes.
Strategic partnerships, regulatory engagement, and preventive strategies will further enhance the potential for growth and impact in this critical area of healthcare.
|
Category |
Projected CAGR through 2031 |
|
Drug Type– Antiplatelet Agents |
3.8% |
|
Route of Administration– Oral |
4.6% |
Antiplatelet Agents Continue to be the Bestseller Category Among Drug Type
Antiplatelet agents indeed continue to be a cornerstone in the treatment of myocardial infarction (MI) and cardiovascular diseases in general. Antiplatelet therapy is a standard component of acute MI treatment protocols. It is initiated early to prevent further ischemic damage and improve outcomes post-MI.
Antiplatelet agents continue to hold the largest market share by drug type in the myocardial infarction therapeutics landscape owing to their proven efficacy in preventing thrombosis and reducing cardiovascular events. Ongoing advancements and research in this field aim to further optimize treatment outcomes and expand options for personalized patient care.
Oral Route of Administration Set to Explore Excellent Prospects
The oral route of administration holds promising prospects in the field of myocardial infarction therapeutics, driven by its convenience, patient acceptance, technological advancements, and integration with digital health solutions.
As pharmaceutical companies continue to innovate and develop new oral therapies, the role of oral medications in managing MI is expected to expand, offering improved outcomes and quality of life for patients worldwide.
|
Region |
CAGR through 2031 |
|
North America |
4.0% |
|
Europe |
4.8% |
North America to be at the Forefront
North America, particularly the US, has a high prevalence of cardiovascular diseases, including myocardial infarction. According to the American Heart Association, heart disease remains a leading cause of death in the region.
The high incidence of risk factors such as obesity, hypertension, diabetes, and sedentary lifestyles contributes significantly to the demand for MI therapeutics.
The region boasts a well-developed healthcare infrastructure, with access to state-of-the-art medical facilities and technologies. This infrastructure supports the effective diagnosis, treatment, and management of MI, driving demand for advanced therapeutics.
Additionally, North America is home to major pharmaceutical and biotechnology companies that invest heavily in research and development. This investment has led to the development of innovative therapies and advanced treatment modalities for MI.
The presence of leading academic and research institutions further supports ongoing clinical trials and medical research.
Europe to Exhibit a Notable CAGR
Europe market is projected to secure a CAGR of 4.8% in the forecast period from 2024 to 2031. Europe has seen a significant rise in the prevalence of cardiovascular diseases, including myocardial infarction.
Lifestyle changes, increasing rates of obesity, diabetes, and hypertension contribute to this trend. The growing number of MI cases necessitates effective therapeutic solutions, driving market growth.
European countries are known for their robust healthcare systems, which provide widespread access to advanced medical care. This infrastructure supports the adoption of innovative MI therapeutics and ensures high standards of patient care, contributing to market expansion.
-therapeutics-market-by-region.webp)
The global myocardial infarction therapeutics market is highly competitive, with several key players actively engaged in research, development, and commercialization of MI treatments.
Major companies are adopting various strategies to strengthen their market position, including mergers and acquisitions, partnerships, and innovative product launches.
February 2021
The European Commission approved Pavix (clopidogrel) for use in adult patients with moderate to high-risk transient ischemic attacks (TIAs) or minor ischemic strokes (IS) within 24 hours of the TIA or IS event in combination with aspirin, according to Sanofi S.A., a global biopharmaceutical company focused on human health. With this new indication, long-term single anti-platelet medication can be administered after a 21-day trial.
|
Attributes |
Details |
|
Forecast Period |
2024 to 2031 |
|
Historical Data Available for |
2018 to 2023 |
|
Market Analysis |
US$ Billion for Value |
|
Key Regions Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled in the Report |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon request |
By Drug Type
By Route of Administration
By Distribution Channel
By Region
To know more about delivery timeline for this report Contact Sales
The demand for MI therapeutics is being driven by several key factors globally. These drivers include increasing prevalence of cardiovascular diseases and advancements in medical technology.
Some of the key players operating in the market are Bayer HealthCare LLC, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Janssen Biotech, Inc., Merck & Co. Inc., Novartis International AG, and Sanofi.
The regions such as North America, Europe, and East Asia are experiencing the highest growth rates in the myocardial infarction (MI) therapeutics market.
The future of myocardial infarction therapeutics is promising, with numerous advancements and innovations on the horizon. Precision medicine, gene and stem cell therapy, regenerative medicine, AI, telemedicine, and novel drug delivery systems are set to revolutionize MI treatment and management.
The US holds the largest share in the global market.
